Sinopharm (01099) released its performance for the six months ended June 30, 2024, with a revenue of 0.295 billion yuan (RMB), a decrease of 2.07% year-on-year; the net profit attributable to owners of the parent company was 3.7039 million yuan, a decrease of 9.76% year-on-year; and the basic earnings per share was 1.19 yuan.
The announcement stated that the decrease in revenue was due to a decline in the group's pharmaceutical retail business and medical device distribution business revenue.